Navigation Links
TessArae, LLC and Chinese esoteric laboratory, Kindstar Global, secure partnership for development of genetic tests.

POTOMAC FALLS, Va., April 25, 2013 /PRNewswire/ -- TessArae®, LLC and Kindstar Global, the largest esoteric reference laboratory in China, have signed a collaboration agreement for the development of a pan-ethnic carrier screen for the Chinese population.  The assay, which will be run in Kindstar's laboratories in China, employs TessArae's targeted sequencing development platform and proprietary bioanalysis software. 

The agreement solidifies a development partnership which allows Kindstar to leverage TessArae's design expertise to create and market its own Laboratory Developed Test (LDT) specific to the Chinese market.  TessArae's development platform combines a highly multiplexed amplification strategy with a standard Affymetrix microarray protocol.  Results are delivered as genomic sequence, automatically generated and analyzed by TessArae's GeneCipher™ algorithms.

Kindstar Founder and CEO, Dr. Shiang Huang said in a statement, "TessArae's development platform is a unique and valuable tool that provides Kindstar near immediate access to key markets with clinically appropriate, sequence-driven diagnostics.   Kindstar is able to capture revenue faster at less cost by partnering with TessArae in the expansion of our test menu."

Dr. Tom Richards , TessArae President and CEO, commented "TessArae's development platform grants our partners the combined benefits of two worlds: the efficiency and predictability of microarrays with the rich specificity of genetic sequencing.  As a result, they can develop market-specific genetics assays much more quickly than alternative approaches.  We are excited to partner with Kindstar in bringing their vision of recessive disease testing to the Chinese market."

Kindstar provides esoteric diagnostic testing services to hospitals and physicians in all Chinese provinces, including more than 3,300 hospitals, among them 930 large leading hospitals, so-called tertiary hospitals. It has laboratories in Beijing, Shanghai, and Wuhan.  Additional company information can be found at

TessArae is privately held by a partnership lead by John W. Marriott III of the Marriott hotel family.  TessArae is recognized as the market leader in targeted sequencing applications using a microarray.  Since its inception, the company has helped design 15 custom assays for a wide variety of partners, including worldwide government agencies, academic institutions and commercial reference laboratories. TessArae's targeted sequencing platform has been analytically validated.  Reference laboratories use the TessArae platform to develop their own custom genetics assays.  Additional company information can be found at

Financial and other terms of the agreement were not disclosed.

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Chinese Scientists Zhen-Yi Wang and Zhu Chen Awarded 7th Annual Szent-Gyorgyi Prize for Progress in Cancer Research
2. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
3. Health Diagnostic Laboratory, Inc. Provides Largest Corporate Gift in Science Museum of Virginias History
4. MRIGlobal, DHMRI Align in Strategic Collaboration
5. - Unigene Secures Financing to Extend Operating Runway in Conjunction with Strategic Reorganization -
6. VG Life Sciences, Inc. Secures Two-Year Funding Commitment and Administrative Support from MedBridge, LLC
7. Nabsys Secures $20 Million Series D Financing to Support Launch of Semiconductor-Based Single-Molecule Platform for Genomic Analysis
8. Unisense FertiliTech A/S Secures an Additional 20 Million USD in New Capital Investment
9. lifeIMAGE Announces No-Cost Service for Hospitals to Give Patients Secure Access to Medical Imaging, Pledges Support for the Blue Button Initiative
10. Blue Marble Biomaterials Secures Distribution Agreement with SAFC
11. Turning smartphones into secure and versatile keys
Post Your Comments:
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. has initiated coverage on the following equities: ... (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing their ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... new line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC ... in Chicago. The result of a collaboration among several companies with expertise in ...
(Date:6/22/2016)... June 22, 2016 Cell Applications, Inc. ... them to produce up to one billion human ... within one week. These high-quality, consistent stem cells ... cells and spend more time doing meaningful, relevant ... proprietary, high-volume manufacturing process that produces affordable, reliable ...
Breaking Biology Technology:
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/12/2016)... , May 12, 2016 , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
Breaking Biology News(10 mins):